Author

C.-T. Tseng

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Biochemistry· 2 Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 5 Research Focus:drug response / drug discovery· 4 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

A. Drelich· 7 shared J. Zhu· 3 shared A. O'Donoghue· 2 shared D. Skinner· 2 shared K. Kempaiah· 2 shared L. Li· 2 shared L. Zhang· 2 shared P. Fajtova· 2 shared

Activity by Year

2020-2021 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersMicrobiology

A. Drelich

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD

H. Ma, Y. Guo, H. Tang, C.-T. Tseng, L. Wang, H. Zong, Z. Wang, Y. He, Y. Chang, S. Wang, H. Huang, Y. Ke, Y. Yuan, M. Wu, Y. Zhang, , J. Zhu

This paper identifies a monoclonal antibody, 2G1, that neutralizes all SARS-CoV-2 variants with high potency and describes its mechanism of action and therapeutic efficacy in animal models.

bioRxiv · Sep 24, 2021Cell Biology

Discovery of highly potent pancoronavirus fusion inhibitors that also effectively inhibit COVID-19 variants from the UK (Alpha), South Africa (Beta), and India (Delta)

F. Curreli, S. Ahmed, S. M. B. Victor, A. Drelich, S. S. Panda, A. Altieri, A. Kurkin, C.-T. Tseng, C. Hillyer, A. Debnath

The paper identifies potent small molecules that inhibit multiple coronaviruses, including SARS-CoV-2 variants, with high selectivity and in vivo efficacy.

bioRxiv · Sep 3, 2021Pharmacology & Toxicology

A Universal Bacteriophage T4 Nanoparticle Platform to Design Multiplex SARS-CoV-2 Vaccine Candidates by CRISPR Engineering

V. B. Rao, J. Zhu, N. Ananthaswamy, S. Jain, H. Batra, W.-C. Tang, D. A. Lewry, M. L. Richards, S. A. David, P. B. Kilgore, J. Sha, A. Drelich, C.-T. Tseng, A. K. Chopra

This paper develops a CRISPR-engineered bacteriophage T4 nanoparticle platform to create multiplex SARS-CoV-2 vaccine candidates, showing potent immune responses and protection in animal models.

bioRxiv · Jan 19, 2021Microbiology

Potent in vitro anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L

A. Ashhurst, A. Tang, P. Fajtova, M. Yoon, A. Aggarwal, A. Stoye, M. Larance, L. Beretta, A. Drelich, D. Skinner, L. Li, T. Meek, J. McKerrow, V. Hook, C.-T. Tseng, , R. J. Payne

bioRxiv · Dec 23, 2020 · PreprintBiochemistry

The Development of a Novel Nanobody Therapeutic for SARS-CoV-2

G. Ye, J. Gallant, C. Massey, K. Shi, W. Tai, J. Zheng, A. Odle, M. Vickers, J. Shang, Y. Wan, A. Drelich, K. Kempaiah, V. Tat, S. Perlman, L. Du, , F. Li

This paper develops a potent, low-cost nanobody therapeutic, Nanosota-1C-Fc, that effectively blocks SARS-CoV-2 infection in vitro and in vivo with high affinity and stability.

bioRxiv · Nov 17, 2020Microbiology

A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells

D. Mellott, C.-T. Tseng, A. Drelich, P. Fajtova, B. C. Chenna, D. Kostomiris, J. C. Hsu, J. Zhu, Z. Taylor, V. Tat, A. Katzfuss, L. Li, M. A. Giardini, D. Skinner, K. Hirata, , J. H. McKerrow

This paper shows that K777, a cysteine protease inhibitor, blocks SARS-CoV-2 infection by inhibiting host cathepsin L, which is required for spike protein processing, with nanomolar efficacy in several cell lines.

bioRxiv · Oct 23, 2020 · PreprintBiochemistry

Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models

W. Li, A. Drelich, D. R. Martinez, L. E. Gralinski, C. Chen, Z. Sun, A. Schäfer, S. R. Leist, X. Liu, D. V. Zhelev, L. Zhang, E. L. Peterson, A. Conard, J. W. Mellors, C.-T. Tseng, , D. S. Dimitrov

This study rapidly identifies a potent human monoclonal antibody against SARS-CoV-2 that neutralizes the virus in animal models and shows promise for therapeutic use.

bioRxiv · May 13, 2020 · PreprintMicrobiology